Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Sanofi (SNY) to EUR 105 from EUR 110 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi Targets Pfizer’s Pneumococcal Stronghold With New Phase 3 Infant Vaccine Trial
- Trump Trade: White House releases details on ‘Great Healthcare Plan’
- Drugmakers concerned about legal risk with FDA review program, Reuters reports
- Sanofi Wins First EU Disease‑Modifying Approval for Type 1 Diabetes Drug Teizeild
- Sanofi downgraded to Neutral from Buy at UBS